Proactive Investors - Run By Investors For Investors

Cannabis company Wayland Group enters the UK by taking 51% stake in Theros Pharma

The investment is important as it will ultimately provide Wayland with access to the UK for the sale and distribution of its products
medical cannabis and lab tech
Wayland will make an initial payment of £3.8 million followed by a second payment of £24 million after milestones are achieved

Canadian cannabis company Wayland Group Inc (CSE:WAYL) (OTCQB:MRRCF) is pushing into the UK by striking a deal to acquire 51% of the British medicinal cannabis company Theros Pharma Ltd.

The investment is important as it will ultimately provide Wayland with access to the UK for the sale and distribution of its products.

“We’re proud to join with Theros on the journey to enhance lives through cannabis, now in the UK,” said Wayland CEO Ben Ward in a statement.

“Theros’s dedicated team of professionals and advocates, who were instrumental in achieving cannabis legalization in the UK will work with Wayland to create access to cannabis for patients and further advocate for personalized medicine,” Ward added.

Under the deal’s terms, Wayland will make an initial payment of £3.8 million followed by a second payment of £24 million after certain milestones are achieved; that includes Theros obtaining a license to cultivate cannabis in the UK or a license to import medical cannabis for use in the UK.

READ: Maricann to rename itself as Wayland Group as it looks to widen its reach in cannabis

The payments will be met by issuing shares of Wayland based on market prices, subject to a floor issue price of $1.65 per share.

Theros is an early stage company that has imported cannabis to the UK for patients with a prescription for medical cannabis. The company was set up by Professor Mike Barnes, a neurologist and medical cannabis campaigner, who helped to obtain the first medical UK cannabis license for Alfie Dingley, a young boy with epilepsy who generated attention in the British press after being denied cannabis to treat his illness.

The case was met with an outpouring of emotion and encouraged the Home Office to make medical cannabis legal in the UK earlier this year.

Founded in 2013 and based in Burlington, Ontario and Munich, Germany, Wayland is a cultivator and processor of cannabis, with a focus on medical varieties.

The company has production operations in Langton, Ontario, Dresden, Germany, Regensdorf, Switzerland and Ibague, Colombia.  

Shares of Wayland, which was until recently known as Maricann, slipped 1.4% to C$1.40 in Monday’s afternoon trading session.


Contact Ellen Kelleher at [email protected]

View full WAYL profile View Profile

Wayland Group Inc Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use